ASTRAZENECA PLC (AZN) Form 6-K — Jul 27, 2026
AstraZeneca announced positive high-level results from the Phase III CLARITY-Gastric01 trial, showing that Sone-Ve demonstrated a statistically significant and clinically meaningful improvement in overall survival for patients with second-line and later CLDN18.2-positive advanced gastric cancers. The trial met its dual primary endpoint of overall survival in third-line and later-line treatment, as well as a key secondary endpoint of overall survival in the overall second-line and later-line population. The data supports expanding the target population to patients with CLDN18.2 expression in at least 25% of tumor cells, representing approximately 60% of patients in this setting.
Key figures
- Annual global deaths
- 650,000
- Patient population eligible
- 60%
- Annual patients 2nd line plus
- 183,500
- Current median survival months
- 5-9
- Recommended phase iii dose mg kg
- 2.2
- Claudin 18 2 positivity threshold
- 25%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.